PBLA

Panbela Therapeutics Inc

PBLA, USA

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

https://www.panbela.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PBLA
stock
PBLA

Panbela Therapeutics Inc (PBLA) Quarterly 10-Q Report qz.com

Read more →
PBLA
stock
PBLA

Panbela Provides Business Update and Reports Q3 2024 Financial Results GlobeNewswire

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2024-09-30)

Rating:

BUY

Target Price:

$500

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

39.48 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-138.78 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 1.08% of the total shares of Panbela Therapeutics Inc

1.

Parametric Tax-Managed Emerg Mkt I

(0.7269%)

since

2025/01/31

2.

Parametric Emerging Markets I

(0.3559%)

since

2025/01/31

3.

Citadel Advisors Llc

(0%)

since

2024/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-09-30

EPS Actual

-1.48

EPS Estimate

-15

EPS Difference

13.52

Surprise Percent

90.1333%

Investing Fit Scorecard

(Last Updated 2024-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2024-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.